Long-term bone marrow damage after chemotherapy for acute myeloid leukaemia does not improve with time

Br J Haematol. 1990 May;75(1):68-72. doi: 10.1111/j.1365-2141.1990.tb02617.x.

Abstract

Thirteen patients with acute myeloid leukaemia (AML) who had been in unmaintained complete remission for at least 5 years following successful chemotherapy, were studied by marrow culture techniques regularly for periods of up to 5 years. In 10 patients, short-term clonal assay revealed the incidence of granulocyte-macrophage progenitor cells (GM-CFC) to be at the lower limit of the normal range; but three showed wide fluctuations in GM-CFC numbers. Moreover the generation of GM-CFC in long-term bone marrow culture (LTBMC) was impaired in eight of nine evaluable patients. These results suggest that, despite normal blood counts, impairment of haemopoiesis persists in patients who are long-term survivors of AML, and this does not improve with the passage of time.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Bone Marrow / drug effects*
  • Bone Marrow / pathology
  • Female
  • Granulocytes / pathology
  • Hematopoiesis / drug effects
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / pathology
  • Macrophages / pathology
  • Male
  • Middle Aged
  • Remission Induction
  • Time Factors
  • Tumor Stem Cell Assay